Hologic hits 52-week high on mammography study | Wall Street Beat
January 10, 2013 by MassDevice staff
Shares of Hologic hit a 52-week high yesterday on a study showing the benefits of mammography using its Selenia 3D device.
Hologic (NSDQ:HOLX) shares hit a 52-week high yesterday on news that mammography using 3D technology significantly improved diagnostic accuracy.
HOLX shares reached their highest level since May 2011 yesterday, peaking at $23.22 apiece before closing at $22.36, up 7.0% on the day. Shares were trading at $22.39 as of about 12:50 p.m. today.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- FDA Issues Draft Guidance to Help Companies Distinguish Between a Voluntary Medical Device Recall and a Product Enhancement
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
Navigation
NEWS
Symbios recalls GoPump and GOBlock kits following patient complaints
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien launches its new respiratory monitoring device
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
New Xbox One Kinect game system can measure heartbeat visually | MassDevice.com On Call
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
MassDevice.com +3 | The top 3 med-tech stories for May 22, 2013
If you read nothing else today, make sure you're still in the know with MassDevice +3.
FDA's Ortho Panel supports down-classification of pedicle screw spinal systems
The FDA's Orthopedic & Rehabilitations Devices Panel agrees with the FDA's recommendations that...
